A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
- PMID: 15944423
- DOI: 10.1056/NEJMoa043876
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
Abstract
Background: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression.
Methods: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score.
Results: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050).
Conclusions: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
Statins for aortic stenosis.N Engl J Med. 2005 Jun 9;352(23):2441-3. doi: 10.1056/NEJMe058070. N Engl J Med. 2005. PMID: 15944429 No abstract available.
-
Lipid-lowering therapy in calcific aortic stenosis.N Engl J Med. 2005 Sep 8;353(10):1066-7; author reply 1066-7. doi: 10.1056/NEJMc051838. N Engl J Med. 2005. PMID: 16148295 No abstract available.
Similar articles
-
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.Heart. 2006 Sep;92(9):1207-12. doi: 10.1136/hrt.2005.080929. Epub 2006 Jan 31. Heart. 2006. PMID: 16449511 Free PMC article. Clinical Trial.
-
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Clinical Trial.
-
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA. 2004 Mar 3;291(9):1071-80. doi: 10.1001/jama.291.9.1071. JAMA. 2004. PMID: 14996776 Clinical Trial.
-
SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory.Expert Rev Cardiovasc Ther. 2015 Apr;13(4):355-67. doi: 10.1586/14779072.2015.1025058. Expert Rev Cardiovasc Ther. 2015. PMID: 25797901 Review.
-
Statin use for nonrheumatic calcific aortic valve stenosis: a review with meta-analysis.J Cardiovasc Med (Hagerstown). 2013 Aug;14(8):559-67. doi: 10.2459/JCM.0b013e3283587267. J Cardiovasc Med (Hagerstown). 2013. PMID: 23032960 Review.
Cited by
-
Visualizing novel concepts of cardiovascular calcification.Trends Cardiovasc Med. 2013 Apr;23(3):71-9. doi: 10.1016/j.tcm.2012.09.003. Epub 2013 Jan 3. Trends Cardiovasc Med. 2013. PMID: 23290463 Free PMC article. Review.
-
Deficiency in the anti-aging gene Klotho promotes aortic valve fibrosis through AMPKα-mediated activation of RUNX2.Aging Cell. 2016 Oct;15(5):853-60. doi: 10.1111/acel.12494. Epub 2016 May 31. Aging Cell. 2016. PMID: 27242197 Free PMC article.
-
Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation.Am J Cardiovasc Dis. 2012;2(1):43-9. Epub 2011 Dec 15. Am J Cardiovasc Dis. 2012. PMID: 22254213 Free PMC article.
-
Lipid-lowering therapy in older persons.Arch Med Sci. 2015 Mar 16;11(1):43-56. doi: 10.5114/aoms.2015.48148. Epub 2015 Jan 8. Arch Med Sci. 2015. PMID: 25861289 Free PMC article.
-
Calcific aortic valve damage as a risk factor for cardiovascular events.Pol J Radiol. 2012 Oct;77(4):30-4. doi: 10.12659/pjr.883626. Pol J Radiol. 2012. PMID: 23269934 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical